In a study of adults with T2DM and proteinuric CKD, baseline 24 h urinary protein (uProt), eGFR, and BMI were strongly predictive of a 30% reduction in uProt after initiating SGLT2 inhibitor therapy. This evidence concerns the gene SLC5A2 and chronic kidney disease.